Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)

NCT03655002 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03655002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03655002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 17, 2019
Completion date
March 2, 2027
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hepatocellular carcinoma, refractory liver carcinoma, stage iv hepatocellular carcinoma ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage ivb hepatocellular carcinoma ajcc v8